U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C60H86N16O13.C2H4O2
Molecular Weight 1299.4762
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUSERELIN ACETATE

SMILES

CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6

InChI

InChIKey=PYMDEDHDQYLBRT-DRIHCAFSSA-N
InChI=1S/C60H86N16O13.C2H4O2/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40;1-2(3)4/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65);1H3,(H,3,4)/t40-,41-,42-,43-,44-,45-,46-,47+,48-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C60H86N16O13
Molecular Weight 1239.4242
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: http://www.netdoctor.co.uk/medicines/sexual-health/a7588/suprecur-buserelin/

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin is used for palliative treatment of prostate cancer, and for treatment of endometriosis. Buserelin is also used for infertility treatment to prepare the pituitary gland before starting treatment with gonadotrophins (FSH and LH) to artificially stimulate ovulation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.12 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SUPREFACT

Approved Use

The palliative treatment (initial and maintenance treatment) of patients with hormonedependent advanced carcinoma of the prostate gland
Primary
SUPREFACT

Approved Use

SUPREFACT® (buserelin acetate) nasal solution is indicated for the treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of treatment is usually six months and should not exceed nine months.
Primary
SUPERCUR

Approved Use

This medicine is used to prepare the pituitary gland before starting treatment with gonadotrophins (FSH and LH) to artificially stimulate ovulation.
PubMed

PubMed

TitleDatePubMed
The neurochemistry of the GnRH pulse generator.
1996
Patents

Sample Use Guides

In Vivo Use Guide
Buserelin is marketed as a nasal spray or as a solution for subcutaneous injections. For palliative treatment of patients with prostate cancer, for the first seven days of treatment give 500 mcg (0.5 mL) every 8 hours should be given by subcutaneous injection. The dose of buserelin in patients with endometriosis is 400 mcg (200 mcg into each nostril) three times daily using the metered-dose pump (nebulizer) provided.
Route of Administration: Other
In Vitro Use Guide
Binding affinity of buserelin towards gonadotrophin-releasing hormone receptor was measured using rat Leydig cells and iodinated buserelin as a radioligand. The iodinated buserelin to a single class of high affinity sites at a KD value of 0.12 nM and the number of binding sites is approx. 2500 per interstitial cell. The agonistic activitt was measured as the potency of the peptides to stimulate and inhibit LHRH-induced LH release in rat anterior pituitary cells in primary culture.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:37:49 UTC 2023
Edited
by admin
on Fri Dec 15 15:37:49 UTC 2023
Record UNII
13U86G7YSP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUSERELIN ACETATE
JAN   MART.   USAN   WHO-DD  
USAN  
Official Name English
SUPRECUR
Brand Name English
Buserelin acetate [WHO-DD]
Common Name English
HOE-766
Code English
BUSERELIN MONOACETATE
MI  
Common Name English
CONCEPTAL
Brand Name English
BUSERELIN MONOACETATE [MI]
Common Name English
BUSERELIN ACETATE [JAN]
Common Name English
BUSERELIN ACETATE [MART.]
Common Name English
BUSERELIN ACETATE [USAN]
Common Name English
NSC-725176
Code English
Classification Tree Code System Code
NCI_THESAURUS C1910
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
Code System Code Type Description
NSC
725176
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
NCI_THESAURUS
C84460
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
EVMPD
SUB00905MIG
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
ChEMBL
CHEMBL2110824
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
PUBCHEM
50224
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
MERCK INDEX
m2776
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID30218712
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
SMS_ID
100000084837
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
DAILYMED
13U86G7YSP
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
FDA UNII
13U86G7YSP
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
DRUG BANK
DBSALT001170
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
CAS
68630-75-1
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY
RXCUI
42569
Created by admin on Fri Dec 15 15:37:49 UTC 2023 , Edited by admin on Fri Dec 15 15:37:49 UTC 2023
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY